Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan
FDA after the storm: drug review delays and increased executive oversight expected
In short reprieve for pharma, commerce secretary says drug tariffs to come 'in the next month or two'
Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug
*please scroll down for all the latest news *
